Europe Lymphedema Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
307.74 Million
USD
608.27 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 307.74 Million |
 Market Size (Forecast Year) |
USD 608.27 Million |
 CAGR |
% |
| Major Markets Players |
|
歐洲淋巴水腫治療市場細分，依治療類型（壓迫療法、手術、藥物療法、雷射療法等）、類型（繼發性淋巴水腫和原發性淋巴水腫）、患處（下肢、上肢和生殖器）、年齡組（成人、老年和兒童）、給藥途徑（口服、注射和外用）、最終用戶（醫院、專科診所、經銷手術中心、經銷手術中心
歐洲淋巴水腫治療市場規模
- 2024 年歐洲淋巴水腫治療市場規模為3.0774 億美元 ，預計 到 2032 年將達到 6.0827 億美元，預測期內複合年增長率為 9.1%。
- 歐洲市場的成長主要得益於淋巴水腫和癌症相關淋巴水腫在該區域的患病率上升，加上診斷成像方式和創新治療方法的重大技術進步，從而改善了對該病症的識別和管理。
- 此外，該地區患者和臨床醫生對更有效、更便捷、更全面的解決方案的需求日益增長，這些解決方案可用於管理慢性腫脹並提升生活質量，這使得先進的壓迫療法、淋巴引流技術和顯微外科幹預成為淋巴水腫治療的現代標準。這些因素共同加速了歐洲淋巴水腫管理解決方案的普及，顯著促進了該行業的區域成長。
歐洲淋巴水腫治療市場分析
- 淋巴水腫的特徵是淋巴系統功能受損引起的慢性腫脹，由於其對患者生活品質有重大影響，通常是癌症治療或遺傳易感性的併發症，因此成為現代醫療保健中越來越重要的關注領域
- 淋巴水腫治療需求不斷增長，主要原因是全球淋巴水腫和癌症相關淋巴水腫盛行率不斷上升、醫護人員和患者意識不斷增強，以及診斷和治療方法的技術不斷進步
- 2024 年，德國在淋巴水腫市場佔據主導地位，這得益於淋巴水腫病例（尤其是癌症相關淋巴水腫）的高發病率、先進的醫療基礎設施以及消費者的強烈意識和對創新療法的早期採用
- 2024 年，壓力療法佔據淋巴水腫治療市場的主導地位，這得益於其作為治療腫脹的一線和最常見治療方法的良好聲譽、其非侵入性，以及壓力服裝和設備的持續創新，從而提高了舒適度和療效
報告範圍和歐洲淋巴水腫治療市場細分
|
屬性 |
歐洲淋巴水腫治療關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
歐洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
歐洲淋巴水腫治療市場趨勢
透過人工智慧和數位整合增強患者護理
- 淋巴水腫市場的一個重要且正在加速發展的趨勢是與人工智慧 (AI) 和數位健康平台的深度融合，涵蓋遠端監控、個人化治療演算法和遠距醫療解決方案。這種技術融合顯著提高了患者的便利性、治療順從性以及慢性病的整體管理。例如，該地區癌症發生率和其他導致淋巴水腫的慢性病負擔日益加重，凸顯出一個關鍵的患者群體正在推動對長期淋巴水腫管理解決方案的需求。
- 人工智慧在淋巴水腫護理中的應用，可以實現多種功能，例如分析海量患者數據以預測潛在的病情復發、根據個體反應優化壓力服的壓力水平，以及提供更聰明的預警以促進早期幹預。例如，一些新興的人工智慧解決方案正在被探索，旨在透過分析影像資料來提高早期淋巴水腫檢測的準確性，並指導患者進行個人化的復健訓練。此外，整合通訊功能的數位平台為患者提供了便利的虛擬問診服務，使他們能夠遠端討論症狀並獲得指導。
- 淋巴水腫監測設備和自我管理工具與更廣泛的數位健康生態系統的無縫集成，有助於集中控制患者護理的各個方面。透過單一介面，使用者可以管理肢體測量數據、治療依從性並與護理團隊溝通，從而創造統一且更主動的健康管理體驗。
- 這種更聰明、直觀、互聯的淋巴水腫管理系統趨勢正在從根本上重塑患者對慢性病護理的期望。因此，各大公司正在開發人工智慧診斷工具和數位平台，這些工具和平台具備自動數據分析、個人化警報和遠端治療調整等功能。
- 隨著臨床醫生和患者越來越重視對這種終身疾病的有效、便捷和全面的管理，對提供無縫 AI 和數位整合的淋巴水腫解決方案的需求在醫療保健環境和患者群體中迅速增長
歐洲淋巴水腫治療市場動態
司機
由於疾病盛行率上升和診斷能力增強，需求不斷增長
- 淋巴水腫盛行率的不斷上升，特別是癌症治療引起的繼發性淋巴水腫，加上診斷技術的加速進步和人們認識的不斷提高，是推動淋巴水腫管理解決方案需求成長的重要因素
- 例如，歐洲患者群體龐大且老化，加上慢性病發病率上升和醫療保健可近性的改善，顯著增加了對有效淋巴水腫管理的需求
- 隨著醫療保健專業人員和患者越來越意識到未治療的淋巴水腫的長期影響並尋求早期幹預，生物阻抗譜 (BIS) 和複雜成像（例如 ICG 淋巴造影）等先進診斷工具可提供精確測量和早期檢測，與傳統捲尺測量相比具有顯著優勢
- 此外，人們越來越重視以患者為中心的護理，並希望改善慢性病患者的生活質量，這使得綜合淋巴水腫管理成為癌症後護理和慢性病管理的一個組成部分，與康復計劃和支持療法無縫銜接
- 早期診斷的便利性、數位健康工具提供的個人化治療方案以及透過先進的壓迫療法和運動療法進行自我管理症狀的能力，是推動淋巴水腫解決方案在臨床和家庭護理環境中廣泛應用的關鍵因素。主動篩檢的趨勢以及使用者友善自我管理產品的日益普及，進一步促進了市場的成長。
克制/挑戰
對診斷不足和高昂治療費用的擔憂
- 淋巴水腫普遍存在漏診和誤診問題，加之持續治療帶來的沉重經濟負擔，對更廣泛的市場滲透和有效的患者護理構成了重大挑戰。由於淋巴水腫早期症狀隱匿，常被醫護人員忽視，導致幹預延誤和病情進展，引發患者對其長期健康狀況的擔憂。
- 例如，在歐洲許多地區，持續的淋巴水腫護理需要大量的自付費用，包括專門的服裝和治療，這可能會給患者帶來沉重的經濟負擔，尤其是在公共健康覆蓋或保險計劃有限的情況下
- 透過加強醫學教育、標準化篩檢方案和公眾意識宣傳活動來解決這些漏診問題，對於改善患者預後至關重要。區域和地方衛生組織經常強調宣傳和教育舉措，以改善早期發現和護理。此外，專用壓力衣、氣動幫浦和手動淋巴引流療法相對較高且持續的費用，對於價格敏感的消費者來說，可能構成持續治療的重大障礙，尤其是在保險覆蓋範圍有限的歐洲地區或面臨經濟壓力的患者。該地區終身管理的自付費用仍然很高。
- 雖然人們的認識正在逐漸提高，但人們認為這種疾病缺乏“治癒方法”，而且這種疾病是慢性的，這仍然會阻礙主動治療，特別是對於那些沒有足夠保險或無法獲得專門護理的人來說
- 透過加強對醫療服務提供者和公眾的教育措施、改善保險報銷政策以及開發更實惠、更容易獲得的淋巴水腫管理方案來克服這些挑戰，對於持續的市場成長和改善數百萬淋巴水腫患者的生活品質至關重要
歐洲淋巴水腫治療市場範圍
市場根據治療類型、類型、受影響區域、年齡層、給藥途徑、最終用戶和分銷管道進行細分。
按治療類型
根據治療類型，淋巴水腫市場細分為壓迫療法、手術、藥物治療、雷射治療和其他療法。壓迫療法預計將在2025年佔據最大的市場收入份額，達到66.87%，這得益於其作為淋巴水腫治療黃金標準的良好聲譽，以及其非侵入性特性，使其適用於廣泛的患者群體。患者通常優先考慮壓迫療法，因為它能夠有效消腫並提高舒適度。由於材料和設計的不斷進步，舒適度和依從性不斷提高，市場對壓力服和壓力泵的需求也強勁。
預計在預測期內，歐洲地區的外科手術領域將迎來最快的增長速度，這得益於淋巴靜脈吻合術 (LVA) 和血管化淋巴結移植術 (VLNT) 等顯微外科技術的不斷進步，以及患者對這些重症病例潛在治癒方案的認識不斷提高。外科手術有望顯著減少長期肢體體積，因此非常適合對保守治療無效的患者。專科淋巴水腫外科中心數量的不斷增加以及對外科手術療效的日益認可，也促進了外科手術的普及。
按類型
歐洲地區的淋巴水腫治療市場依類型分為原發性淋巴水腫和繼發性淋巴水腫。預計到2025年，繼發性淋巴水腫將佔據最大的市場收入份額，達到79.05%，這主要得益於該地區淋巴水腫的盛行率顯著升高，這主要歸因於淋巴結清除術和放射治療等癌症治療。由於繼發性淋巴水腫與挽救生命的癌症幹預措施相關且發病更容易識別，醫療保健提供者和患者通常優先考慮繼發性淋巴水腫的治療。隨著癌症存活率的提高以及人們對其治療後併發症的認識不斷提高，市場對針對繼發性淋巴水腫的解決方案的需求也十分強勁。
預計原發性淋巴水腫領域將在預測期內實現最快的增長，這得益於人們對這種常伴有遺傳性和早發性疾病的認識和診斷能力的提高，以及基因檢測和兒科淋巴水腫專科護理的進步。對原發性淋巴水腫相關基因突變的深入了解有助於更早診斷。
按受影響區域
根據受影響區域，歐洲淋巴水腫治療市場細分為下肢、上肢和生殖器。預計下肢淋巴水腫治療市場將繼續佔據歐洲地區最大的市場收入份額，佔53.95%，這與全球趨勢相符。這主要歸因於歐洲部分地區絲蟲性淋巴水腫的高發生率，以及與慢性靜脈功能不全相關的淋巴水腫病例的增加，以及婦科和前列腺癌發生率的上升。歐洲地區患有下肢淋巴水腫的患者通常因嚴重的功能障礙、行動不便和不適而尋求治療，這導致對治療方案的需求持續增長。
預計歐洲上肢淋巴水腫市場在預測期內將迎來最快的成長，這得益於該地區乳癌倖存者人數的不斷增加。乳癌治療，尤其是腋窩淋巴結清除術和放射治療，仍然是上肢淋巴水腫的主要危險因子。歐洲腫瘤患者和醫療保健提供者對手臂淋巴水腫篩檢、早期診斷和介入的認識不斷提高，推動了對客製化解決方案的需求。專用上肢袖套和氣動加壓裝置的持續發展和普及，進一步促進了其市場份額的不斷增長。
按年齡組
歐洲淋巴水腫治療市場按年齡層細分為成人、老年和兒童。成人市場 預計將繼續佔據歐洲地區最大的市場收入份額。這主要是由於與癌症治療（例如乳腺癌、婦科癌和前列腺癌的治療）相關的繼發性淋巴水腫發病率高，由於生活方式的改變、環境因素以及癌症診斷技術的進步，這些疾病在歐洲成年人口中日益普遍。此外，各種後天因素，包括創傷、感染（例如某些流行地區的絲蟲病）和其他疾病，都會導致成人淋巴功能障礙。由於歐洲成年患者群體龐大且對現有治療方案的認識日益加深，他們已成為尋求淋巴水腫治療的最大群體。此外，市場還受益於專為成人淋巴水腫管理量身定制的廣泛產品和解決方案。
預計老年醫學領域將在預測期內成為歐洲地區成長最快的領域。這一加速增長的動力源於歐洲老齡人口的顯著增長，而老齡人口更容易受到與年齡相關的淋巴功能衰退的影響，導致淋巴功能下降。慢性靜脈功能不全、肥胖和其他與年齡相關的慢性疾病等併發症的盛行率不斷上升，也導致老年人淋巴水腫的發生率上升。隨著許多歐洲國家預期壽命的持續增長，老年人慢性疾病（包括淋巴水腫）的負擔也隨之增加。
依給藥途徑
根據給藥途徑，歐洲淋巴水腫治療市場分為口服、注射和外用。預計到2025年，口服藥物將佔據歐洲地區最大的市場份額，達到51.84%。這得益於輔助藥物的便利性，例如用於控制腫脹症狀的利尿劑、用於預防或治療復發性蜂窩性組織炎（淋巴水腫的常見併發症）的抗生素以及各種抗發炎藥物，可在家中使用。此外，人們對旨在改善淋巴功能的新興口服療法的興趣和研究也日益增多。歐洲患者通常喜歡口服藥物，因為它們易於自行服用，這有助於患者在臨床治療之外更好地遵守治療計劃。
預計注射劑市場將在預測期內成為歐洲地區成長最快的領域。這項快速擴張得益於新型生物療法、生長因子（例如刺激淋巴再生的VEGF-C）和基因療法的持續研發。這些先進的治療方法通常需要腸外（注射）給藥，以有效刺激淋巴再生、減輕發炎或調節病情進展。
按最終用戶
根據最終用戶，全球淋巴水腫治療市場可細分為醫院、專科診所、門診手術中心 (ASC) 和其他類型。預計醫院將佔據最大市場份額。這種優點歸功於醫院能夠提供全方位的淋巴水腫治療方案——從早期保守療法（如手動淋巴引流和壓迫療法）到先進的外科手術（如淋巴靜脈吻合術和血管化淋巴結移植）。醫院也是複雜或晚期病例的主要轉診點，這些病例需要多學科護理，包括影像學、診斷和外科幹預。
預計專科診所細分市場將在預測期內實現最快的成長。這一增長主要得益於越來越多專注於淋巴水腫的康復和門診護理中心的出現，這些中心提供非侵入性治療和慢性病管理。這些診所專門服務於需要定期治療的輕度至中度淋巴水腫患者，使其成為經濟實惠且便捷的醫院就診替代方案。日益增加的宣傳活動和政府主導的慢性水腫管理舉措，尤其是在城市地區，進一步推動了專科診所的蓬勃發展。
按分銷管道：
根據分銷管道，全球淋巴水腫治療市場可細分為藥局、商店、直接招標和其他管道。預計直接招標管道將佔據市場主導地位。這主要是因為公立醫院、復健中心和政府衛生機構大量採購醫療設備，例如壓力幫浦、防護衣和手術包。直接招標管道確保採購流程精簡、符合監管標準並獲得優惠價格，使其成為大型機構買家的首選。
預計門市細分市場（包括零售和線上通路）將成為預測期內成長最快的細分市場。這種快速擴張歸因於患者行為轉向居家淋巴水腫管理，尤其是在新冠疫情之後。線上購物的便利性、電商滲透率的不斷提升以及壓力袖套和繃帶等自我管理設備的普及，加速了該細分市場的成長。此外，遠距醫療服務的興起使患者能夠在家中管理早期淋巴水腫，從而增加了對非處方藥和電商治療工具的依賴。
歐洲淋巴水腫治療市場區域分析
- 2024 年，歐洲在淋巴水腫治療市場佔有 29.28% 的份額，這得益於淋巴水腫病例（尤其是癌症相關淋巴水腫）的高發病率、強大的醫療基礎設施以及對醫學研發的大量投資
- 該地區的醫療保健提供者和患者高度重視專科診所和醫院提供的現成的先進診斷工具、全面的治療方案以及日益增多的宣傳活動
- 高可支配收入、強大的醫療保險滲透率以及對慢性病管理的積極態度進一步支持了這種廣泛採用，將淋巴水腫護理確立為癌症倖存者和其他淋巴系統疾病患者治療路徑的組成部分
德國淋巴水腫治療市場洞察
德國淋巴水腫市場在歐洲佔據了相當大的收入份額，2024年通常佔比超過17.45%，這得益於先進診斷工具的快速普及以及整合淋巴水腫護理的日益普及。醫療保健專業人員和患者越來越重視透過綜合治療方案對淋巴水腫進行早期發現和有效管理。臨床醫師對淋巴水腫的認識日益加深，加上對專業壓迫療法、氣動幫浦和數位健康監測的強勁需求，進一步推動了淋巴水腫產業的發展。此外，諸如淋巴水腫全民健保等扶持政策的日益完善，以及生物阻抗譜(BIS)和遠端病患監測平台的技術進步，也顯著促進了市場擴張，提高了病患獲得長期照護的管道和依從性。
英國淋巴水腫治療市場洞察
英國淋巴水腫市場在歐洲佔據了15.30%的顯著收入份額，為2025年的區域增長做出了重大貢獻，這得益於先進診斷工具的逐步普及以及國家醫療服務體系（NHS）對綜合淋巴水腫護理的日益重視。英國各地的醫療保健專業人員和患者越來越重視透過協調一致的治療方案和多學科護理方法對淋巴水腫進行早期發現和綜合管理。臨床醫生對淋巴水腫的認識不斷提高，加上對專用壓力服、氣動壓力裝置和新興數位醫療工具的需求不斷增長，正在穩步推動英國淋巴水腫市場的發展。此外，淋巴水腫支持網路等國家倡導組織和NHS倡導教育和患者可近性的舉措的支持作用，以及生物阻抗譜（BIS）和遠端患者管理平台等診斷方式的技術進步，也促進了市場的擴張。這些努力正在提高及時診斷的可近性，並促進長期照護策略的依從性，最終改善英國淋巴水腫患者的預後。
歐洲淋巴水腫治療市佔率
淋巴水腫治療產業主要由知名公司主導，包括：
- Tactile Medical（美國）
- Essity Aktiebolag (publ)（瑞典）
- 3M（美國）
- 康德樂（美國）
- Lohmann & Rauscher GmbH & Co. KG（德國）
- PAUL HARTMANN AG（德國）
- medi GmbH & Co. KG（德國）
- 康維特公司（英國）
- Juzo（德國）
- Smith + Nephew（英國）
- SIGVARIS集團（瑞士）
- Sanyleg Srl（義大利）
- Avet Pharmaceuticals Inc.（美國）
- ThermoTek Inc.（美國）
- Huntleigh Healthcare Limited（英國）
- KOYA醫療（美國）
- AIROS Medical, Inc.（美國）
- 生物壓縮系統（美國）
- Mego Afek ltd.（以色列）
- SIGVARIS集團（瑞士）
- Sanyleg Srl（義大利）
- 蘇珊（法國）
歐洲淋巴水腫治療市場的最新發展
- 2025年3月，BSN Medical（愛生雅旗下公司）宣布了一項旨在加強歐洲傷口護理教育的新計劃，旨在讓更多醫療專業人士掌握慢性傷口管理方面的先進知識，包括與淋巴水腫相關的知識。該計劃側重於循證實踐和產品創新，以改善患者預後。
- 2025年4月，Lohmann & Rauscher (L&R) 集團收購了法國一家領先的醫療器材分銷商，顯著增強了L&R在法國醫院和家庭護理領域淋巴水腫產品的市場地位和准入。這項策略性舉措旨在利用L&R豐富的產品組合，擴大其在歐洲的影響力。
- 2025年2月，medi GmbH & Co. KG 推出了專為下肢淋巴水腫設計的升級版壓力服系列，該系列採用增強的透氣性和符合人體工學的設計，以提高患者的舒適度和依從性。此次推出的產品滿足了人們對舒適、隱密的長期管理解決方案日益增長的需求。
- 2024年10月，Juzo GmbH推出了用於治療上肢淋巴水腫的全新「JuzoFlex」壓力襪系列，該系列採用更輕薄的布料，並提供創新的尺寸選擇。這些服裝專為日常穿著而設計，方便穿戴，旨在提高患者的依從性並改善生活品質。
- 2024年7月，SIGVARIS AG宣布與歐洲知名遠距醫療平台合作，整合遠距病患監測功能，用於淋巴水腫管理。此次合作使患者能夠追蹤肢體測量數據和治療依從性，從而方便與護理團隊進行線上諮詢。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS –
4.3.1 MICRO AND MACROECONOMIC FACTORS
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.3.3 KEY PRICING STRATEGIES
4.3.4 ANALYSIS AND RECOMMENDATION
4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 MERGERS & ACQUISITIONS
4.4.1.2 TECHNOLOGY COLLABORATIONS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES & MILESTONES
4.4.5 INNOVATION STRATEGIES & METHODOLOGIES
4.4.6 RISK ASSESSMENT & MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PIPELINE ANALYSIS – EUROPE LYMPHEDEMA TREATMENT MARKET
4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.5.2 DRUG THERAPY PIPELINE
4.5.3 PHASE III CANDIDATES
4.5.4 PHASE II CANDIDATES
4.5.5 PHASE I CANDIDATES
4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH)
4.5.7 CONCLUSION
4.6 EPIDEMIOLOGY–
4.6.1 INCIDENCE OF LYMPHEDEMA (EUROPE & BY GENDER)
4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER
4.6.3 TREATMENT RATE
4.6.4 MORTALITY RATE
4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.6.6 PATIENT TREATMENT SUCCESS RATES
4.7 TARIFF
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 Europe vs. Regional Tariff Structures
4.7.2.2 United States: Medicare/Medicaid Tariff Policies, CMS Pricing Models
4.7.2.3 European Union: Cross-border Tariff Regulations and Reimbursement Policies
4.7.2.4 Asia-Pacific: Government-imposed Tariffs on Imported Medical Products
4.7.2.5 Emerging Markets: Challenges in Tariff Implementation
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 Import Duties on Prescription Drugs vs. Generics
4.7.3.2 Impact on Drug Affordability and Access
4.7.3.3 Key Trade Agreements Affecting Pharmaceutical Tariffs
4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.7.4.1 Cost Burden on Hospitals and Healthcare Facilities
4.7.4.2 Effect on Patient Affordability and Insurance Coverage
4.7.4.3 Tariffs and Their Role in Medical Tourism
4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.7.5.1 WTO Regulations on Healthcare Tariffs
4.7.5.2 Impact of Trade Wars on the Healthcare Supply Chain
4.7.5.3 Role of Free Trade Agreements (FTAs) in Reducing Tariffs
4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
5 REGULATORY FRAMEWORK–
5.1 NORTH AMERICA
5.2 SOUTH AMERICA
5.3 EUROPE
5.4 ASIA-PACIFIC
5.5 MIDDLE EAST & AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY
6.1.2 INCREASE IN THE PREVALENCE OF CANCERS
6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS
6.2 RESTRAINTS
6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT
6.2.2 LACK OF AWARENESS ABOUT THE DISEASE
6.3 OPPORTUNITIES
6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS
6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS
6.4 CHALLENGES
6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT
6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES
7 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 COMPRESSION THERAPY
7.3 SURGERY
7.4 DRUG THERAPY
7.5 LASER THERAPY
7.6 OTHERS
8 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 SECONDARY LYMPHEDEMA
8.3 PRIMARY LYMPHEDEMA
9 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
9.1 OVERVIEW
9.2 LOWER EXTREMITY
9.3 UPPER EXTREMITY
9.4 GENITALIA
10 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 GERIATRIC
10.4 PEDIATRIC
11 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 INJECTABLE
11.4 TOPICAL
12 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 PHARMACY STORES
13.3 DIRECT TENDER
13.4 OTHERS
14 EUROPE LYMPHEDEMA TREATMENT MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 UNITED KINGDOM
14.1.4 ITALY
14.1.5 RUSSIA
14.1.6 SPAIN
14.1.7 TURKEY
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 POLAND
14.1.12 AUSTRIA
14.1.13 HUNGARY
14.1.14 NORWAY
14.1.15 IRELAND
14.1.16 LITHUANIA
14.1.17 REST OF EUROPE
15 EUROPE LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TACTILE MEDICAL
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 ESSITY AKTIEBOLAG (PUBL)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 3M
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 CARDINAL HEALTH
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 LOHMANN & RAUSCHER GMBH & CO. KG
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 AIROS MEDICAL, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ARJO
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 AVET PHARMACEUTICALS INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BAUERFEIND
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BIOCOMPRESSION SYSTEMS
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 CONVATEC INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 ENOVIS CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 HUNTLEIGH HEALTHCARE LIMITED
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 IMPEDIMED LIMITED
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT/NEWS
17.15 JODAS EXPOIM PVT. LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 JUZO
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 KOYA MEDICAL
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 LLC BINNOPHARM GROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 MCKESSON MEDICAL-SURGICAL INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 MEDI GMBH & CO. KG
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 MEDTRONIC
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MEGO AFEK LTD
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 PAUL HARTMANN AG
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 PERFORMANCE HEALTH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PURETECH HEALTH INC
17.25.1 COMPANY SNAPSHOT
17.25.2 PIPELINE PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 SANYLEG SRL A SOCIO UNICO
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 SIGVARIS GROUP
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SMITH+NEPHEW
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENT
17.29 THERMOTEK
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 THUASNE
17.30.1 COMPANY SNAPSHOT
17.30.2 PRODUCT PORTFOLIO
17.30.3 RECENT DEVELOPMENT
17.31 VIATRIS INC.
17.31.1 COMPANY SNAPSHOT
17.31.2 REVENUE ANALYSIS
17.31.3 PRODUCT PORTFOLIO
17.31.4 RECENT DEVELOPMENT
17.32 WHITE SWAN PHARMACEUTICAL
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 PRODUCTS AND THEIR STAGES IN DEVELOPMENT.
TABLE 2 PHASE-WISE DISTRIBUTION: CLINICAL TRIALS
TABLE 3 PHASE 2 CANDIDATES
TABLE 4 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 6 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2018-2032 (USD THOUSAND)
TABLE 7 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 8 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 9 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 10 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 EUROPE LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 EUROPE SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 21 EUROPE LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 EUROPE UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 EUROPE GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 EUROPE ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 EUROPE GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 EUROPE PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 29 EUROPE ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 EUROPE INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 EUROPE TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 33 EUROPE HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 EUROPE SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 EUROPE AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 EUROPE PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 EUROPE DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 EUROPE LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 42 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 44 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 45 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 46 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 47 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 48 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 53 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 54 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 59 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 60 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 61 GERMANY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 62 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 63 GERMANY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 GERMANY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 GERMANY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 68 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 69 GERMANY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 70 GERMANY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 GERMANY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 74 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 75 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 76 FRANCE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 77 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 78 FRANCE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 FRANCE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 FRANCE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 83 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 84 FRANCE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 85 FRANCE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 86 FRANCE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 87 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 89 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 90 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 91 UNITED KINGDOM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 92 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 93 UNITED KINGDOM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 UNITED KINGDOM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 UNITED KINGDOM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 98 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 99 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 104 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 105 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 106 ITALY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 107 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 108 ITALY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 ITALY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 ITALY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 ITALY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 ITALY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 113 ITALY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 114 ITALY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 115 ITALY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 116 ITALY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 117 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 119 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 120 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 121 RUSSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 122 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 123 RUSSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 RUSSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 RUSSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 128 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 129 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 130 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 131 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 132 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 134 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 135 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 136 SPAIN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 137 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 138 SPAIN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 SPAIN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 SPAIN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 143 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 144 SPAIN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 145 SPAIN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 146 SPAIN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 147 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 149 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 150 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 151 TURKEY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 152 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 153 TURKEY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 TURKEY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 TURKEY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 158 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 159 TURKEY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 160 TURKEY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 161 TURKEY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 162 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 164 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 165 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 166 NETHERLANDS COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 167 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 168 NETHERLANDS SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 NETHERLANDS DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 NETHERLANDS PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 173 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 174 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 175 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 176 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 177 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 179 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 180 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 181 SWITZERLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 182 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 183 SWITZERLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 SWITZERLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 SWITZERLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 188 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 189 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 190 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 191 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 192 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 194 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 195 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 196 BELGIUM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 197 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 198 BELGIUM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 BELGIUM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 BELGIUM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 203 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 204 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 205 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 206 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 207 POLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 POLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 209 POLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 210 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 211 POLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 212 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 213 POLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 POLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 POLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 POLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 POLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 218 POLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 219 POLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 220 POLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 221 POLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 222 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 224 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 225 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 226 AUSTRIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 227 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 228 AUSTRIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 AUSTRIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 AUSTRIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 233 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 234 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 235 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 236 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 237 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 239 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 240 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 241 HUNGARY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 242 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 243 HUNGARY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 HUNGARY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 HUNGARY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 248 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 249 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 250 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 251 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 252 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 254 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 255 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 256 NORWAY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 257 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 258 NORWAY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 NORWAY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 NORWAY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 263 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 264 NORWAY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 265 NORWAY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 266 NORWAY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 267 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 269 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 270 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 271 IRELAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 272 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 273 IRELAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 IRELAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 IRELAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 278 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 279 IRELAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 280 IRELAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 281 IRELAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 282 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 284 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 285 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 286 LITHUANIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 287 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 288 LITHUANIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 LITHUANIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 LITHUANIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 293 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 294 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 295 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 296 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 297 REST OF EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 REST OF EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 299 REST OF EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
图片列表
FIGURE 1 EUROPE LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LYMPHEDEMA TREATMENT MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 FIVE SEGMENTS COMPRISE THE EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE (2024)
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 EUROPE LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 14 INCREASE IN THE PREVALENCE OF CANCERS IS EXPECTED TO DRIVE THE EUROPE LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHEDEMA TREATMENT MARKET IN 2025 AND 2032
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDONESIA ZEOLITE MARKET
FIGURE 17 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2024
FIGURE 22 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 23 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 24 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2024
FIGURE 26 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2025-2032 (USD THOUSAND)
FIGURE 27 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2025-2032)
FIGURE 28 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 29 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 30 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 31 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 32 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 33 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 34 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 35 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 36 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, 2024
FIGURE 38 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 39 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 40 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 42 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 43 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 44 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 EUROPE LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 46 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
